Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation.

Effect of a Higher Dose of Alpha-1 Antitrypsin Augmentation Therapy on Lung Inflammation in Subjects With Alpha-1 Antitrypsin Deficiency.

NCT01669421•Michael Campos, MD

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Alpha 1 Antitrypsin Deficiency

Interventions

Alpha-1 Antitrypsin (human)

Locations

United States

Locations (1)

Division of Pulmonary and Critical Care, Human Reseach, U of Miami

Miami, Florida, United States

Key Dates

Start Date

July 1, 2012

Primary Completion Date

May 1, 2016

Completion Date

May 1, 2016

Last Updated

May 8, 2019

Sponsors

Lead Sponsor

Michael Campos, MD

Collaborators

CSL Behring

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 8, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions